AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Portfolio Pulse from Vandana Singh
HC Wainwright initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with a Buy rating and a price target of $55, citing potential superior efficacy of its investigational arthritis drug rosnilimab compared to Eli Lilly's (NYSE:LLY) peresolimab. Gilead Sciences Inc (NASDAQ:GILD) also mentioned for its BTLA agonist study expansion.
July 22, 2024 | 6:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a price target of $55, highlighting the potential superior efficacy of its investigational arthritis drug rosnilimab compared to Eli Lilly's peresolimab.
The Buy rating and high price target from HC Wainwright, along with the potential superior efficacy of rosnilimab, are likely to positively impact ANAB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Gilead Sciences' expansion of its BTLA agonist study boosts confidence in AnaptysBio's ANB032, a high-risk/high-reward asset.
The expansion of Gilead's BTLA agonist study is a positive development but has a neutral short-term impact on GILD's stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 30
NEUTRAL IMPACT
Eli Lilly's peresolimab is mentioned as a comparator to AnaptysBio's rosnilimab, with the latter potentially having a better efficacy profile.
While AnaptysBio's rosnilimab may have a better efficacy profile, the impact on Eli Lilly's stock is neutral in the short term as peresolimab has already shown encouraging results.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50